Adagrasib review describes survival outcomes but cannot establish a survival advantage
A single-arm analysis pooled outcomes in a genetically defined cancer population. Adverse events were frequent, and there was no comparison group in the pooled analysis.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
This abstract-based review describes survival and tumor-control outcomes among patients treated with adagrasib. Because the pooled analysis had no comparison group, it cannot show how much the medicine extended survival or whether it outperformed another treatment. Frequent adverse events also matter when interpreting the reported outcomes in this specific mutation-defined cancer population.
Without a comparison group, the analysis cannot establish a treatment-related survival benefit. The abstract also leaves tumor-specific results, follow-up duration, and the distribution of adverse-event severity unclear.
What researchers found
Reported pooled median overall survival
Among adagrasib-treated patients; no comparison group. Follow-up duration was unspecified, and this estimate is not added survival time.
Survival time versus survival benefit
The reported median overall survival describes outcomes in the treated groups. It is not an estimate of months gained from treatment, because the analysis does not provide an untreated or alternative-treatment group for comparison.
Tolerability remains part of the picture
The review reported frequent adverse events and highlighted dose modifications and variable response rates. Its abstract does not provide enough detail to weigh specific harms against outcomes for an individual tumor type.
The original publication
Clinical Outcomes and Safety Profile of Adagrasib in KRAS G12C-Mutated Solid Tumors: A Single-Arm Meta-Analysis.
Ahmad O, Rath S, Banatwala UESS et al.
Am J Clin Oncol · 2026
- PubMed ID
- 40844328
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.